The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Historically, there has been limited evidence to suggest the appropriate treatment sequencing of this melanoma patient population. However, new findings demonstrate starting with Opdivo plus Yervoy ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate long-term survival results in the Phase 3 ...
Combination treatment with two PD-1 inhibitors — Yervoy and Opdivo — did not improve survival without cancer recurrence compared with Opdivo alone in patients with high-risk melanoma, a type of skin ...
Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too. The BMS immunotherapy ...
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic ...
Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. The dual immunotherapy combination of Opdivo and Yervoy showed it can ...
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...
(Reuters) -Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial treatment for a type of liver cancer. The ...
On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...
Opdivo + Yervoy cut cancer progression or death risk by 79% vs. chemo in first-line MSI-H/dMMR colorectal cancer patients. PFS at 12 months was 79% with Opdivo + Yervoy vs. 21% with chemo; median PFS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback